Waldenstrom Macroglobulinemia

Oncology·MeSH: Waldenstrom Macroglobulinemia

Prevalence

5.0 / 100K

5 drugs in development·3 companies·18 clinical trials

Drug Pipeline by Phase

Compare drugs

iopofosine i 131 fractionated dose vs iopofosine i 131 multiple doseiopofosine i 131 fractionated dose vs iopofosine i 131 single doseiopofosine i 131 fractionated dose vs apg2575

Frequently asked questions

How many drugs are in development for Waldenstrom Macroglobulinemia?

BioSniper tracks 5 drugs in development for Waldenstrom Macroglobulinemia across 3 companies.

How many clinical trials target Waldenstrom Macroglobulinemia?

There are 18 clinical trials targeting Waldenstrom Macroglobulinemia tracked by BioSniper.

What is the prevalence of Waldenstrom Macroglobulinemia?

The estimated prevalence of Waldenstrom Macroglobulinemia is approximately 5.0 per 100,000 population.

Deep-dive into Waldenstrom Macroglobulinemia

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Waldenstrom Macroglobulinemia — Drugs in Development & Clinical Trials | BioSniper